Oncolytics' Cleverly Cut Subgroup Data Unlikely To Save Reolysin In NSCLC

August appears to be month of bad news for clinical developments in non-small cell lung cancer (NSCLC). Following Bristol-Myers Squibb Co.'s shocking Phase III failure for Opdivo (nivolumab) in first-line NSCLC, Oncolytics Biotech Inc. has also reported disappointing data for its lung cancer drug Reolysin.

Men and women split on sides, separation crack. Concept 3D illustration.

Oncolytics Biotech reported less than impressive Phase II NSCLC data for its cancer drug Reolysin (pelareorep) this week – and despite the company's best attempt to find statistical significant data in subgroup analyses, analysts are not convinced.

The Canadian firm reported on Aug. 10 data split by gender from the Phase II IND211 study, which enrolled patients with both non-squamous (adenocarcinoma) and squamous cell histology. Patients with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

02 Jun 2025

• By Joseph Haas

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP

02 Jun 2025

• By Mary Jo Laffler

Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

02 Jun 2025

• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.